Previous close | 0.4300 |
Open | 0.4350 |
Bid | 0.4350 x 122481900 |
Ask | 0.4400 x 33847800 |
Day's range | 0.4300 - 0.4400 |
52-week range | 0.1450 - 0.4550 |
Volume | |
Avg. volume | 17,932,968 |
Market cap | 1.524B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | 22.00 |
EPS (TTM) | 0.0200 |
Earnings date | 21 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.43 |
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
With its stock down 9.1% over the past three months, it is easy to disregard Red 5 (ASX:RED). However, the company's...
** Novo Nordisk notched a win in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for $16.5 billion. ** Brazilian fashion companies Arezzo & Co and Grupo Soma said they had agreed to a merger to form an entity with yearly revenues of 12 billion reais ($2.42 billion), which will be 54% controlled by Arezzo. ** Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said.